A previous study by the authors (Leiker and Carling, 1966) suggested that a dosage of 200 or 400 mg of DDS weekly was not sig nificantly less effective than one of 600 to 800 mg weekly. In the present study 3 groups of lepromatous patients (14 in all) were treated for 21 months with DDS, 3 of them receiving 250 mg weekly (Group 1), 5 a dose of 50 mg (Group 2) and 6 one of 20 mg of the drug weekly (Group 3).
All the patients were clinically, bacterio logically and histologically lepromatous. Most of them had received previous treatment, but all were still strongly bacteriologically positive when the trial was started. At the beginning of the trial and then every 3 months thereafter smears were taken from 6 sites and examined locally. The bacteriological indices are shown in Table 1 .
In addition biopsy specimens were taken every 3 months, each time from the same lesion, near to but just avoiding the scar of previous biopsies. These specimens were assessed blindly, the dosage group to which the patient belonged being unknown to the investigator. Assessment was based on the percentage of sections occupied by infiltration, the bacterial index (B.I.), the 54 percentage of morphologically intact bacilli, the percentage of fragmented bacilli, and the per centage of granular bacilli . Deeply and evenly stained bacilli were recorded as intact and regarded as alive. Bacilli showing a slightly irregular staining but not broken up by un stained parts were recorded as fragmented-a proportion of these bacilli may still have been alive. Bacilli which were broken up into a number of granules were recorded as granular and were regarded as being dead. The results of examination of the biopsy material are shown in Table 2 . The frequency of lepromatous re actions occurring during the 2 years immediately before the trial and also those during the trial was recorded; the numbers are shown in Fig. 1 .
RESULTS
In all 3 groups the percentage of infi ltration decreased, the average decrease being 15% per annum . The differences between the groups in this respect are not significant.
In all groups the B.I. decreased significantly, the decrease being about 1.0 per annum. This is about the same rate of decrease as has been found elsewhere in patients receiving 600 mg of DDS weekly. In the patients treated with 20 to Lepr. Rev. 2 . 0 1.9
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Total 12 21 50 mg of DDS weekly the decrease was on the average slightly less in the 2nd year of treatment than in the 1st year.
As most patients had received previous treatment the percentage of intact bacilli was already low at the beginning of the trial. In only one patient a few intact bacilli, accom panied by an increase in the percentage of fragmented bacilli, reappeared after 15 months of treatment. This patient had received 300 mg of DDS weekly.
In most patients the percentage of fr ag mented bacilli began to decrease during the first 3 months of treatment and in all groups a marked decrease was seen in the second 3 months. In most patients in all 3 groups 90 % or more of the bacilli had become granular after one year of treatment. Further increase in the percentage of granular bacilli was slower in all groups. However, none of the patients had become bacteriologically. negative at the end of the trial.
Groups 1 and 2 showed no significant difference in frequency of lepromatous reactions before and during the trial, but in Group 3 the frequency of reactions increased during the trial . TABl.E 2
Results of biopsies at 3-rnonthly intervals 
DISCUSSION
The number of patients in the trial was ad mittedly small. The frequency of detailed observations, however, was high. The bacterio logical changes in most patients of all groups showed basically the same trend. All patients improved during the trial. This improvement, however, cannot be entirely ascribed to the activity of the drug. The shift from fragmented bacilli to granular bacilli and , the decrease in the B.!. were probably to a large D. L. Leiker and D. Carling 57 extent due to removal of dead bacilli from the tissues by the body itself and not due to the effect of the drug . It is, however, significant that during 15 months of treatment intact bacilli did not reappear in any of the patients treated with the lower dosages of DDS, and that after 15 months only a few intact bacilli appeared temporarily in a few patients who had shown frequent reactions. This suggests that even these low dosages do inhibit the multi plication of bacilli. The slightly slower decrease in the percentage of fragmented bacilli found in the first 6 months in the groups treated with 20 and 50 mg of DDS weekly, as compared with the group given 250 mg weekly, suggests that the lower dosages are somewhat less effective than the higher. Until fu rther trials in un treated lepromatous patients or patients with a higher percentage of intact bacilli have pro duced more information about the exact degree of efficacy of the lower dosages it seems wise to regard a dosage of about 200 mg of DDS weekly as adequate for patients with uncomplicated lepromatous reactions. In pa,tients with frequent rer.ctions the lower dosages may be used, as they are doubtless still efficacious, although the bacteriological effect is possibly not optimal.
In this trial the frequency of reactions was highest in patients receiving the lowest dosage of DDS. This is not surprising because 5 out of the 6 patients in this group had already shown reactions before the trial and the tendency to becoming reactive frequently increases when sulphones, even in a lower dosage, are continued. The outcome of this trial does not show that patients who are intolerant of a high dosage of sulphones will necessarily tolerate a lower dosage. It is possible that patients who have not yet become truly sensitized to sulphones may benefit from a lower dosage, but it is doubtful if the real problem cases will do so in regard to frequency of reactions.
The 4 patients who had frequent reactions while receiving 20 mg of DDS weekly improved bacteriologically, no intact bacilli reappearing in any significant numbers. There is, however, a danger that, although the number of bacilli in the infiltrates, which can be easily demonstrated by skin smears and skin biopsies, declines, the bacilli which may be concealed at as yet un identified sites are not killed by a low dosage of DDS. Such bacilli may become resistant to the drug. The fact that lepromatous patients who have been treated with a higher dosage of DDS not infrequently relapse when treatment is withdrawn soon after skin smears and biopsies have become negative is regarded as evidence that such hidden fo ci of living bacilli exist and that these bacilli are not easily killed by treatment.
The present trial has not produced a final answer to the question of the most effective dosage of DDS. There is still an urgent need for more detailed studies on the optimal dosage of sulphones.
SUMMARY
(I) Three groups of lepromatous patients were treated respectively with 250, 50 or 20 mg of DDS weekly for 21 months.
(2) Bacteriological progress was assessed by examination of 3-monthly smears and by serial biopsies, each time from the same lesion.
(3) All patients improved bacteriologically. The differences in acteriological progress be tween the groups were not marked. It is possible that 250 mg of DDS weekly is slightly more effective than the lower dosages.
(4) The frequency of reactions was not sig nificantly lower in patients treated with the lower doses. The highest frequency of reactions was found in patients treated with the lowest dosage but several patients in this group had already shown frequent reactions prior to the trial.
(5) The decrease in bacillary index cannot be ascribed entirely to the effect of the drug, but is partly due to removal of dead bacilli by the body itself. The fact, however, that intact bacilli did not reappear suggests that very low dosages are effective.
(6) Relapse was frequently seen when treat ment was stopped soon after smears and skin biopsies had become negative, suggesting that there were hidden fo ci of living bacilli. As it is not certain that such bacilli too are killed by low dosages and drug resistance may develop, it is suggPRted that about 200 mg of DDS weekly may be regarded as an adequate dosage for patients with uncomplicated lepromatous leprosy, until further evidence for the efficacy of lower dosages is shown.
